AstraZeneca (AZN) said Friday that its late-stage trial of its therapy, Imfinzi, when combined with standard BCG induction and maintenance therapy, showed significantly improved disease-free survival in patients with high-risk non-muscle-invasive bladder cancer.
The company said the trial was not statistically powered to formally test overall survival but a descriptive analysis demonstrated no detriment.
The drugmaker said the therapy did not raise new safety concerns and did not compromise patients' ability to complete BCG induction and maintenance therapy.
A second experimental arm evaluating Imfinzi combined with BCG induction-only therapy compared to BCG induction and maintenance therapy alone failed to meet the endpoint of disease-free survival, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.